Idiopathic pulmonary fibrosis has no cure, and the drug most commonly prescribed to slow it, Ofev, has carried a five-figure monthly price tag for years. That changes on January 1, 2027, when Medicare’s negotiated maximum fair price takes Ofev’s monthly cost from $12,622 to $6,350, a cut of exactly 50 percent that the Centers for Medicare & Medicaid Services set as part of the drug-negotiation program’s second cycle. Unlike a newly approved drug rushed onto a negotiation list, Ofev has been on the market for more than a decade, and the timing of its inclusion traces to a specific statutory clock rather than to how expensive it happens to be today.
A seven-year rule that put a pulmonary fibrosis drug on CMS’s list
Idiopathic pulmonary fibrosis is a progressive lung disease in which scar tissue builds in the lungs for no identified cause, gradually reducing a patient’s ability to breathe over months or years with no cure available. Ofev does not reverse that scarring; it slows the rate at which lung function declines, which is why patients typically stay on the capsule indefinitely rather than for a fixed course of treatment, a pattern that turns even a moderate monthly price into a large annual one over time.
Ofev’s active ingredient, nintedanib, is FDA-approved to treat idiopathic pulmonary fibrosis along with two related diagnoses, chronic fibrosing interstitial lung disease with a progressive phenotype and interstitial lung disease associated with systemic sclerosis, according to the drug’s FDA prescribing information, which lists Boehringer Ingelheim Pharmaceuticals as the manufacturer. CMS Administrator Mehmet Oz’s agency selected Ofev for this second negotiation cycle alongside 14 other drugs covering cancer, diabetes, psoriasis and other chronic conditions.
The Inflation Reduction Act allows CMS to select a small-molecule drug like Ofev for negotiation only after it has been on the market for at least seven years past its FDA approval date, compared with 11 years for a biologic, according to an analysis by the health policy research organization KFF. Ofev’s original FDA approval dates to 2014, well past that seven-year mark by the time CMS selected this cycle’s drugs, which is part of why a medication treating a comparatively small patient population still qualified for negotiation alongside far higher-volume drugs.
Inside the kit: Alongside 51 state Medicare cost-help packs, The Medicare Cost & Coverage Protection Kit lays out the prior-authorization appeal steps, relevant when a pulmonary fibrosis prescription like Ofev needs a plan’s sign-off before a negotiated price applies at all. Read the prior-authorization appeal steps in The Medicare Cost & Coverage Protection Kit.
Boehringer Ingelheim’s Ofev falls to $6,350, one of ten small-molecule cuts
Of the 15 drugs in this negotiation cycle, ten are small-molecule pills or capsules like Ofev, subject to the seven-year eligibility window, while the rest are biologics subject to the longer 11-year window, a split that shapes which older, established drugs show up on a given year’s list rather than only the newest blockbusters. Ofev’s negotiated price of $6,350, down from $12,622, sits at exactly the halfway point of a list, or 50 percent, matching the reduction CMS reached separately for the breast-cancer drug Ibrance and the leukemia drug Calquence, even though the three drugs have nothing in common medically.
Nintedanib also carries a mechanism distinct from most other drugs in this cycle: it blocks several growth-factor receptors involved in the scarring process rather than targeting cancer cells directly, which is one reason Ofev’s negotiation proceeded on its own timeline within the broader IPF drug market rather than being compared against a close competitor with an identical mechanism. A second FDA-approved drug for the same disease, pirfenidone, works through a different pathway and was not among the 15 drugs CMS selected for this particular cycle, leaving Ofev as the only idiopathic-pulmonary-fibrosis treatment with a negotiated Part D price for 2027.
Savings that show up in Part D’s ledger before they show up in a copay
CMS’s 2027 what’s-new fact sheet lists the negotiated prices for the next 15 drugs, Ofev among them, as taking effect on the same January 1, 2027 date as several other program changes, including expanded telehealth flexibility and a new comparison tool tied to TrumpRx.gov. The fact sheet frames the price change as one line among several rather than as a standalone announcement specific to any single drug.
Because Part D’s redesigned benefit already limits a beneficiary’s annual out-of-pocket drug spending once a fixed dollar threshold is reached, a lower negotiated price for a high-cost drug like Ofev often reduces what the federal government, the Part D plan and Boehringer Ingelheim divide among themselves more than it reduces what an individual patient pays directly once that annual cap is reached. Earlier in a plan year, before the cap is hit, the lower negotiated price still reduces a patient’s percentage-based coinsurance bill during the deductible and initial-coverage phases.
CMS’s own accounting of the round, published alongside the fact sheet, put the combined effect of all 15 negotiated drugs at an estimated $12 billion in net savings for Part D, a roughly 44 percent reduction against what those drugs would otherwise have cost the program, with about 5.3 million of the program’s 53 million enrollees having used one of the 15 drugs in 2024. Ofev’s individual contribution to that total is not broken out separately from the other 14 drugs in the published figures.
What a seven-year eligibility rule does not settle at the pharmacy counter
CMS’s fact sheet fixes what Ofev costs the program starting January 1, 2027, but it does not say whether a specific Part D plan still requires prior authorization for a pulmonary fibrosis prescription, or which state-level cost-help programs might apply before that new price date arrives.
The Medicare Cost & Coverage Protection Kit includes 51 state Medicare cost-help packs and the prior-authorization appeal steps, matching a state-specific cost-help option to the appeal process a denied prescription may require.
Look up the state cost-help pack and the appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
